Am J Gastroenterol

1. PATEL N, Silvey S, Bajaj JS
   Vonoprazan Is Associated with Better Liver-Related Outcomes Compared to Proton Pump Inhibitors In Cirrhosis.
   Am J Gastroenterol. 2026 Feb 10. doi: 10.14309/ajg.0000000000003945.
   

   >> Share

   
   
2. KARLIN KL, Gilbert EH, Lim F, Agyekum AA, et al
   Proton Pump Inhibitors are More Cost-Effective than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease.
   Am J Gastroenterol. 2026 Feb 10. doi: 10.14309/ajg.0000000000003943.
   

   >> Share

   
   

   
   BMC Gastroenterol

3. LIN X, Wang S, Guan Y, Wang H, et al
   Trends and inequities in peptic ulcer mortality across the United States, 1999-2023.
   BMC Gastroenterol. 2026 Feb 12. doi: 10.1186/s12876-026-04671.
   

   >> Share

   
   

   
   BMC Surg

4. SEMEYA AA, Elmokadem E, Hafez RSAA, Siam M, et al
   Preoperative Hill's classification as a predictor of postoperative gastroesophageal reflux disease following laparoscopic sleeve gastrectomy: a prospective multicenter study from Egypt.
   BMC Surg. 2026 Feb 12. doi: 10.1186/s12893-026-03531.
   

   >> Share

   
   

   
   Helicobacter

5. NYSSEN OP, Ortega GJ, Jonaitis L, Perez-Aisa A, et al
   Long-Term Effect of Macrolides on Helicobacter pylori Eradication: Data From the European Registry on Helicobacter pylori Management (Hp-EuReg).
   Helicobacter. 2026;31:e70107.
   

   >> Share

   
   

   
   J Gastroenterol

6. SUGIMOTO M, Murata M
   Future of gastric cancer elimination through Helicobacter pylori eradication therapy in Japan.
   J Gastroenterol. 2026 Feb 7. doi: 10.1007/s00535-026-02356.
   

   >> Share

   
   

   
   Scand J Gastroenterol

7. QI R, Zhou F
   Efficacy analysis of a bismuth-containing quadruple therapy with vonoprazan for Helicobacter pylori infection.
   Scand J Gastroenterol. 2026 Feb 8:1-6. doi: 10.1080/00365521.2026.2622659.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share